کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
6087981 1207683 2016 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Review ArticlePrognostic and predictive markers in pancreatic adenocarcinoma
ترجمه فارسی عنوان
بررسی مقاله نشانگرهای پیشگیرانه و پیش آگهی در آدنوکارسینوما پانکراس
کلمات کلیدی
شیمی درمانی، سرطان پانکراس متاستاتیک، نشانگر پیش بینی شده، نشانگر پیش آگهی،
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی غدد درون ریز، دیابت و متابولیسم
چکیده انگلیسی

Pancreatic ductal adenocarcinoma is characterized by a poor prognosis and a low median survival, despite improvements observed for many other solid tumours. Intensive research efforts have been undertaken during the last decades to discover new prognostic and treatment predictive biomarkers for pancreatic ductal adenocarcinoma. The mainstay of medical treatment for the disease has been the well-tolerated nucleoside analogue, gemcitabine. The only targeted agent currently used in pancreatic ductal adenocarcinoma patients is the epithelial growth factor receptor inhibitor erlotinib in combination with gemcitabine. Recently, treatment regimens such as a combination of fluorouracil-leucovorin-irinotecan-oxaliplatin (FOLFIRINOX) and the combination of nab-paclitaxel with gemcitabine have been introduced for metastatic pancreatic ductal adenocarcinoma. Although these treatment regimens significantly improve survival of patients, there are no good predictive biomarkers available that can be used to identify who would benefit most from them. Therefore, the search for predictive biomarkers that would facilitate personalization of chemotherapy is highly relevant.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Digestive and Liver Disease - Volume 48, Issue 3, March 2016, Pages 223-230
نویسندگان
, , ,